Ethylene vinyl alcohol copolymer erosions after use as a urethral bulking agent.
BACKGROUND
Ethylene vinyl alcohol copolymer was approved for use by the U.S. Food and Drug Administration (FDA) in December 2004 for the treatment of stress urinary incontinence.


METHODS
We report on two patients who underwent injection with ethylene vinyl alcohol copolymer who were later found to have urethral erosions.


CONCLUSIONS
Information regarding complications after ethylene vinyl alcohol copolymer urethral injections is currently limited. We performed a search of the FDA labeling information, Manufacturer and User Facility Device Experience database, and abstracts presented at scientific meetings regarding complications with this material. Symptomatic and asymptomatic erosions of ethylene vinyl alcohol copolymer in the urethra, bladder, and vaginal mucosa are possible complications after this procedure.
Erekson
Elisabeth A
EA
Brown Medical School, Providence, Rhode Island 02903, USA. EErekson@wihri.org
Sung
Vivian W
VW
Rardin
Charles R
CR
Myers
Deborah L
DL
D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D016208:Databases, Factual; D003937:Diagnosis, Differential; D005260:Female; D005548:Foreign-Body Migration / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D007267:Injections; D011145:Polyvinyls / Q000008:administration & dosage / Q000009:adverse effects*; D019736:Prostheses and Implants / Q000009:adverse effects*; D014521:Urethra / Q000601:surgery*; D014550:Urinary Incontinence, Stress / Q000601:surgery*
D011145:Polyvinyls; C020320:ethylene-vinyl alcohol copolymer